Having a quick source of sugar, such as glucose tablets or juice, on hand can prevent severe complications
10.1111/j.1742-1241.2011.02656.x Summary Keywords incretin hormones, GLP-1 receptor agonists, DPP-4 inhibitors, cardiovascular outcomes trials, clinical trials, incretin biology, type 2 diabetes Citation Gilbert MP and Pratley RE (2020) GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
Can you lose weight after one year on semaglutide
In mid-2024, the Endocrine Society warned that online prescribing of compounded GLP-1s poses patient safety risks and undermines public confidence in obesity care. The organization called for stricter verification of clinicians and for oversight of digital compounding networks that have limited traceability or pharmacovigilance. Their concern echoed that of the FDA , which, after investigating multiple adverse-event reports linked to unapproved semaglutide, issued formal warnings to both compounders and telehealth distributors
